Cefazolin

Generic Name: Cefazolin

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄N_₈O_₄S_₃

CAS Number: 25953-19-9

Unique Ingredient Identifier: IHS69L0Y4T

Background: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication: Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions: Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections

Associated Therapies: Antibiotic pre-surgical prophylaxis

Clinical Trials

Comparing of Cefazolin Plus Azithromycin Versus Cefazolin in Prevention of Febrile Morbidity After Emergency Cesarean Delivery

Not Applicable

Completed

Conditions: Febrile Morbidity After Emergency Cesarean Section

Interventions: Drug: Azithromycin Injection [Zithromax]
Drug: Cefazolin
Drug: Sodium Chloride 0.9% Intravenous Solution

First Posted Date: 2022-12-13

Last Posted Date: 2024-01-25

Lead Sponsor: Rajavithi Hospital

Target Recruit Count: 172

Registration Number: NCT05647993

Locations: 🇹🇭
Rajavithi Hospital, Bangkok, Thailand

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Phase 4

Recruiting

Conditions: Surgical Site Infection

Interventions: Drug: Cefazolin
Drug: Water for injection

First Posted Date: 2022-07-07

Last Posted Date: 2024-11-22

Lead Sponsor: Monash University

Target Recruit Count: 9180

Registration Number: NCT05447559

Locations: 🇦🇺
Sir Charles Gairdner, Nedlands, Western Australia, Australia
🇦🇺
Fiona Stanley Hospital, Perth, Western Australia, Australia
🇦🇺
St Vincent's Hospital, Melbourne, Australia

and more 19 locations

Cefazolin PK Study 3g vs 2g

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefazolin

First Posted Date: 2022-04-04

Last Posted Date: 2022-10-12

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 24

Registration Number: NCT05309304

Locations: 🇺🇸
Baxter Investigational Site, Baltimore, Maryland, United States

Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement

Not Applicable

Withdrawn

Conditions: Vascular Access Ports

Interventions: Drug: Cefazolin
Other: saline

First Posted Date: 2022-03-31

Last Posted Date: 2024-04-26

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Registration Number: NCT05304871

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

Phase 1

Completed

Conditions: Infections

Interventions: Drug: Cefazolin 3gm for Injection USP and Dextrose Injection USP

First Posted Date: 2022-01-25

Last Posted Date: 2025-02-28

Lead Sponsor: B. Braun Medical Inc.

Target Recruit Count: 12

Registration Number: NCT05205486

Locations: 🇺🇸
IACT Health - Roswell - IACT - HyperCore - PPDS, Columbus, Georgia, United States
🇺🇸
Hightower Clinical, LLC, Oklahoma City, Oklahoma, United States

Staphylococcus Aureus Network Adaptive Platform Trial

Phase 4

Recruiting

Conditions: Staphylococcus Aureus Bacteremia

Interventions: Radiation: Whole body FDG PET/CT Imaging
Drug: Penicillin
Other: Effectiveness of early switch to oral antibiotics
Drug: Cefazolin
Drug: Clindamycin
Drug: Vancomycin

First Posted Date: 2021-11-30

Last Posted Date: 2024-06-05

Lead Sponsor: University of Melbourne

Target Recruit Count: 8000

Registration Number: NCT05137119

Locations: 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇨🇦
Hôpital Régional de Saint Jérôme, Saint-Jérôme, Quebec, Canada
🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands

and more 146 locations

Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial

Phase 4

Recruiting

Conditions: Pregnancy Complications
Anti-Bacterial Agents
Azithromycin
Physiological Effects of Drugs
Obstetric Labor Complications
Uterine Cervical Incompetence
Preterm Birth
Obstetric Labor, Premature
Cefazolin

Interventions: Drug: Cefazolin and indomethacin
Drug: Azithromycin 1 gram IV

First Posted Date: 2021-11-24

Last Posted Date: 2023-06-26

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 50

Registration Number: NCT05132829

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rutgers Robert Wood Johnson, New Brunswick, New Jersey, United States

The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma

Phase 1

Active, not recruiting

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8
Clinical Stage IA Cutaneous Melanoma AJCC v8
Clinical Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIC Cutaneous Melanoma AJCC v8
Pathologic Stage I Cutaneous Melanoma AJCC v8
Pathologic Stage IB Cutaneous Melanoma AJCC v8
Pathologic Stage IIA Cutaneous Melanoma AJCC v8
Clinical Stage IB Cutaneous Melanoma AJCC v8
Clinical Stage II Cutaneous Melanoma AJCC v8